医薬品受託製造の世界市場規模、シェア、成長分析：サービス別、エンドユーザー別、地域別 - 産業予測（2024年～2031年）

世界の医薬品受託製造の市場規模は、2022年に190億米ドルと評価され、予測期間（2024年～2031年）のCAGRは5.9%で、2023年の201億2,000万米ドルから2031年には318億2,000万米ドルに成長する見通しです。

世界の医薬品受託製造市場は、いくつかの主要促進要因によって力強い成長を遂げています。この分野では、医薬品製造を専門の第三者メーカーにアウトソーシングすることで、製薬会社は中核機能に集中することができます。主な成長要因としては、費用対効果の高い製造への需要の高まり、柔軟な製造へのシフト、非中核業務のアウトソーシング傾向の高まりなどが挙げられます。さらに、医薬品開発の複雑さと専門的な製造能力の必要性が市場拡大を後押ししています。競合情勢には、多様な受託製造サービスを提供する数多くの大手企業が名を連ねています。先進技術の採用と医薬品サプライチェーンのグローバル化が予想されることから、市場は今後数年間で持続的な成長を遂げるものと思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次・一次情報源
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析と影響
  • 競争企業間の敵対関係
  • 代替品の脅威
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 供給企業の交渉力

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術の進歩
• 規制情勢
• ケーススタディ

医薬品受託製造市場規模：サービス別、CAGR（2024年～2031年）

• 医薬品製造サービス
• 医薬品開発サービス
• 生物製剤製造サービス
• 包装およびラベル付けサービス
• 充填仕上げサービス
• その他のサービス

医薬品受託製造市場規模：エンドユーザー別、CAGR（2024年～2031年）

• 大手製薬会社
• 中小製薬会社
• ジェネリック医薬品会社
• その他のエンドユーザー

医薬品受託製造市場規模：地域別、CAGR（2024年～2031年）

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • スペイン
  • フランス
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比の比較（2021年～2023年）

主要企業プロファイル

• Thermo fisher scientific inc.
• Lonza
• Catalent, inc.
• Wuxi apptec
• Sharp Services, LLC
• Samsung biologics
• Boehringer ingelheim international gmbh
• Evonik industries ag
• Fujifilm holdings corporation
• Abbvie inc.
• Siegfried holding ag
• Merck kgaa
• Almac group
• Charles river laboratories
• Asymchem inc.
• Vetter pharma
• Alcami corporation
• Piramal pharma solutions
• Syngene international limited
• Cambrex corporation

結論と推奨事項

Global Pharmaceutical Contract Manufacturing Market size was valued at USD 19 billion in 2022 and is poised to grow from USD 20.12 billion in 2023 to USD 31.82 billion by 2031, growing at a CAGR of 5.9% in the forecast period (2024-2031).

The Global Pharmaceutical Contract Manufacturing market is experiencing robust growth, fueled by several key drivers. This sector involves outsourcing drug production to specialized third-party manufacturers, enabling pharmaceutical companies to concentrate on their core functions. Key growth factors include a rising demand for cost-effective production, a shift towards flexible manufacturing, and an increasing tendency to outsource non-core activities. Furthermore, the complexity of drug development and the necessity for specialized manufacturing capabilities are propelling market expansion. The competitive landscape features numerous major players providing diverse contract manufacturing services. With the anticipated adoption of advanced technologies and the globalization of pharmaceutical supply chains, the market is poised for sustained growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmaceutical Contract Manufacturing Market Segmental Analysis

Global Pharmaceutical Contract Manufacturing Market is segmented by Services, End User and Region. Based on Services, the market is segmented into Pharmaceutical manufacturing services, Drug development services, Biologics manufacturing services, Packaging & labelling services, Fill-finish services, and Other services. Based on End User, the market is segmented into Big pharmaceutical companies, Small & medium-sized pharmaceutical companies, Generic pharmaceutical companies, and Other end users. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmaceutical Contract Manufacturing Market

A key driver of the Global Pharmaceutical Contract Manufacturing market is the rising demand for cost-effective and efficient manufacturing solutions. Pharmaceutical companies are increasingly turning to contract manufacturing organizations (CMOs) to outsource their production processes, aiming to lower operational expenses and concentrate on their core strengths. This strategic shift not only enables them to tap into specialized expertise and advanced technologies but also facilitates streamlined operations, improved resource management, and faster time-to-market for their products. As a result, this trend significantly enhances their competitiveness in the pharmaceutical landscape, driving growth within the contract manufacturing sector.

Restraints in the Global Pharmaceutical Contract Manufacturing Market

One significant restraint impacting the Global Pharmaceutical Contract Manufacturing market is the stringent regulatory requirements and quality standards that govern the industry. Contract Manufacturing Organizations (CMOs) are obligated to comply with a variety of regulatory frameworks, including Good Manufacturing Practices (GMP), which are critical for ensuring the safety, efficacy, and quality of pharmaceutical products. Adhering to these regulations often demands substantial investments in infrastructure, advanced equipment, and skilled personnel, which can be both time-consuming and costly. Non-compliance poses serious risks, including regulatory penalties, damage to reputation, and potential product recalls, creating considerable challenges for CMOs operating in this market.

Market Trends of the Global Pharmaceutical Contract Manufacturing Market

The global pharmaceutical contract manufacturing market is witnessing a robust trend of increasing outsourcing by pharmaceutical companies, driven by significant factors such as cost efficiency, enhanced production flexibility, and the need for specialized skills. As companies seek to streamline operations and allocate resources more effectively, reliance on contract manufacturing organizations (CMOs) has surged, enabling firms to concentrate on their core areas like research and development. This shift not only facilitates scalability but also accelerates time-to-market for new drugs, fostering innovation within the industry. As a result, CMOs are becoming critical partners in navigating the complexities of pharmaceutical production.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Pharmaceutical Contract Manufacturing Market Size by Services & CAGR (2024-2031)

• Pharmaceutical manufacturing services
• Drug development services
• Biologics manufacturing services
• Packaging & labelling services
• Fill-finish services
• Other services

Global Pharmaceutical Contract Manufacturing Market Size by End User & CAGR (2024-2031)

• Big pharmaceutical companies
• Small & medium-sized pharmaceutical companies
• Generic pharmaceutical companies
• Other end users

Global Pharmaceutical Contract Manufacturing Market Size by Region & CAGR (2024-2031)

• North America (Services, End User)
  • US
  • Canada
• Europe (Services, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Services, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Services, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Services, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Thermo fisher scientific inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi apptec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sharp Services, LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer ingelheim international gmbh
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evonik industries ag
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm holdings corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbvie inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried holding ag
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck kgaa
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles river laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asymchem inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetter pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcami corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal pharma solutions
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene international limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation